The Musk Animal Testing Panel Is Riddled With Possibilities.

Published Date: 06 May 2023

A board overseeing animal research has been staffed by insiders from Elon Musk's brain-implant business who could profit financially as the company advances.

Read Full News

Latest News

Medline Draws Another US FDA Warning in Two Months Over Quality Lapses

The U.S. FDA issued a warning letter to medical device maker Medline over violations of manufacturing quality standards, the ⁠second such action against the company in two...

Boehringer Ingelheim Launches AI Centre for Pharma Research in London

German drugmaker Boehringer Ingelheim is launching a centre for artificial intelligence and machine learning ⁠in London, it said on Monday, as it seeks to expand its AI...

How Much Do Long Wait Times Cost Canadian Patients?

Long wait times for surgery and medical treatment cost Canadians over $4.2 billion in lost wages and productivity in 2025.

Virtual Physiotherapy Shows Promise for Chronic Cough

A single 1-hour virtual group physiotherapy intervention for chronic cough achieves high uptake and reduces cough severity and frequency.

Germans Trust ‘Dr AI’ More Than Doctors Who Use It

Nearly half of Germans consult AI before seeing a physician, and some rate chatbot advice as equal to a medical second opinion.

Neurology Clinics are Adopted by Genetic Therapies.

There are new treatments for genetic neuromuscular diseases in the works, which will present challenges for neurologists as well as opportunities for patients.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

The U.S. FDA issued a warning letter to medical device maker Medline over violations of manufacturing quality standards, the ⁠second such action against the company in two...

German drugmaker Boehringer Ingelheim is launching a centre for artificial intelligence and machine learning ⁠in London, it said on Monday, as it seeks to expand its AI...

Long wait times for surgery and medical treatment cost Canadians over $4.2 billion in lost wages and productivity in 2025.

A single 1-hour virtual group physiotherapy intervention for chronic cough achieves high uptake and reduces cough severity and frequency.

Nearly half of Germans consult AI before seeing a physician, and some rate chatbot advice as equal to a medical second opinion.

There are new treatments for genetic neuromuscular diseases in the works, which will present challenges for neurologists as well as opportunities for patients.

News All Time

Gastroenterology Exam Is a Failure for ChatGPT Bot.

The AI language-processing model did not pass a self-assessment test with a minimum passing grade of 70% and is not advised for use in medical education.

Hippocratic AI Raises Funds to Create Healthcare Models.

A startup developing artificial intelligence models for the healthcare sector, Hippocratic AI, has raised $50 million in a larger-than-normal seed funding round.

WHO Issues Warning Against Misinformation When Using AI in Healthcare.

On Tuesday, the World Health Organization warned against using AI in public healthcare because the data it uses to make decisions may be biased or misapplied.

US Jury Rules in Favor of Natera in Cancer-Detection Patent Case.

Monday, a federal jury in Delaware was persuaded to award genetic testing company Natera Inc. $19.3 million in damages from Invitae Corp.'s ArcherDX for infringing patents pertaining to cancer detection.

Changes in Hypertrophic Cardiomyopathy Risk Stratification?

Data show that compared to 24-hour monitoring, extended ECG monitoring detects a higher incidence of clinically relevant arrhythmias.

New Trials in Breast Cancer: Could Your Patient Benefit?

Perhaps one of your patients qualifies to participate in a clinical trial that is currently looking for breast cancer patients.

Drugmakers increase their research spending and look for deals.

As the larger players in the sector look for new sources of long-term revenue, drugmakers announced on Thursday that they are open to acquisitions and that their R&D spending has increased.

EU Law Reform Could Lead to a Shift in Investments: GSK.

The European Union's pharmaceutical industry is governed by new laws, which the British pharmaceutical company GSK warned on Wednesday run the risk of driving businesses to innovate and invest elsewhere.

Proposed Drug Law Reforms Published by the EU.

On Wednesday, Brussels released a long-awaited draft of its proposed overhaul of the laws governing the pharmaceutical industry in the European Union, setting off a dispute with drugmakers who threaten to invest and innovate elsewhere.

BioNTech and DualityBio will develop cancer drugs worth more than $1.5 billion

German company BioNTech said on Monday that it has signed an agreement with Chinese biotech company DualityBio to jointly develop and commercialize two cancer drug candidates.

Musk's brain transplant company seeks human collaboration

Elon Musk's neuroimplantation company Neuralink has reached one of the largest neurosurgical centers in the country capable of testing partners as it plans to test human devices if the regulator.

FDA moves to quickly approve gene therapy

The FDA is making important changes to gene therapy development, including encouraging the use of biomarkers that help recommend treatments for serious conditions, FDA officials said.

AI pab kwv yees ulcerative colitis remission/activity, relapse.

AI tools can distinguish between functional and histological clearance and predict the severity of ulcerative colitis biopsies, and can play a role in clinical trials and routine practice.

The fall of SVB casts a shadow over the beginnings of American biotechnology

The Silicon Valley banking meltdown will leave biotech start-ups with different funding options, investors and analysts said Monday.

SVB shock could have chilling effect on UK biotech sector

HSBC's bailout of the UK branch of the Silicon Valley bank has saved Britain's main biotech sector from collapse, but funding a sector the government sees as essential for the growth of the future economy could be affected, according to industry executives.

The risk of stent infection is low but can be reported

A review of stent coronary artery disease has led researchers to question whether these events are underreported.

Recommended News For You

What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis

One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.

Recommended Articles For You

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis 

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

Iron Metabolism and Inflammatory Disorders: Mechanisms, Clinical Implications, and Therapeutic Approaches 

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

2.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

3.

Biomarker panel offers hope for early pancreatic cancer detection

4.

Financial hardship common in patients with cancer

5.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

1.

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms

2.

Emerging Methods in Hematology in Clinical Decision-Making

3.

Fatigue Rehabilitation in Blood Disorders

4.

Digital Morphology Libraries for Hematology Education: Transforming Diagnostic Training and Clinical Practice

5.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

Early Cancer Detection Saves Lives

3.

The Role of Hemoglobin in Maintaining Healthy Oxygen Levels

4.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

5.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot